Why Compass Pathways Stock Slumped This Week
Shares of the psychedelic healthcare company Compass Pathways (NASDAQ: CMPS) sank by nearly 30% through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. Last Tuesday, the company reported its 2021 third-quarter earnings results ahead of the opening bell.
But the real needle-mover for Compass this week was clearly the positive phase 2b trial results for its lead product candidate, COMP360, as a novel therapy for treatment-resistant depression (TRD). The company announced these highly anticipated trial results immediately before its Q3 earnings report Tuesday morning. COMP360 is a psilocybin-based treatment, which is administered in a guided session by a trained therapist. Psilocybin is the main hallucinogenic compound found in magic mushrooms.
Image source: Getty Images.
Source Fool.com
